Akiyama Shintaro, Lin Austin, Traboulsi Cindy, Rubin David T
Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL.
ACG Case Rep J. 2021 Nov 24;8(11):e00690. doi: 10.14309/crj.0000000000000690. eCollection 2021 Nov.
Alopecia areata (AA) is a type of immune-mediated hair loss and is reported in patients with inflammatory bowel disease. This suggests that there might be a shared molecular pathway in the pathogenesis of AA and inflammatory bowel disease. In addition, tumor necrosis factor-alpha antagonists are also rarely associated with new-onset AA. We present a patient with Crohn's disease treated with adalimumab who developed AA that rapidly progressed to alopecia totalis and universalis. We describe the use of tofacitinib, a Janus kinase 1/3 inhibitor, to not only successfully treat the AA but also maintain her Crohn's disease.
斑秃(AA)是一种免疫介导的脱发疾病,在炎症性肠病患者中也有报道。这表明在斑秃和炎症性肠病的发病机制中可能存在共同的分子途径。此外,肿瘤坏死因子-α拮抗剂也很少与新发斑秃相关。我们报告了一名接受阿达木单抗治疗的克罗恩病患者,该患者出现了斑秃,并迅速发展为全秃和普秃。我们描述了使用托法替布(一种Janus激酶1/3抑制剂),不仅成功治疗了斑秃,还维持了她的克罗恩病病情。